MEDICO REMEDIES LTD.
A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE
Manufacturers of Pharmaceutical Formulations
CIN : L24230MH1994PLC077187
GSTIN- 27AABCM8349L1ZY.
Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • Website : www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Date: 13th August, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 **Scrip Code: 540937**	**National Stock Exchange of India Limited** 5th Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400051 **Symbol: MEDICO**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 13th August, 2026 has, inter alia considered and approved the following:

1. Quarterly Standalone Financial Results of the Company for the quarter ended on 30th June, 2026 along with the Limited Review Report thereon; (enclosed);
2. Re-appointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director of the Company;
3. Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Wholetime Director of the Company;
4. Increase in Remuneration payable to Mr. Harshit Mehta (DIN: 05144280) Managing Director of the Company; and
5. Notice of 32nd AGM of the Company

The requisite disclosure pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as **Annexure 'A'.**

We wish to inform you that the Board Meeting commenced today at 3:30 P.M. and concluded at 05:20 P.M.

Kindly take the same on record.

Thanking you,

FOR MEDICO REMEDIES LIMITED

HARESH MEHTA
Digitally signed by HARESH MEHTA
Date: 2026.08.13 17:27:20 +05'30'

HARESH MEHTA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 01080289
Encl: As above

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • **Website :** www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Annexure-A

Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024

Re-appointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director of the Company

Sr. No.	Requirement of Disclosure		Details
1	**Reason of change viz. appointment~~, resignation, removal, death or otherwise~~**	:	Mr. Rishit Mehta has re-appointed as Whole-Time Director of the Company w.e.f. 18th September, 2026.
2	**Date of Appointment/~~cessation~~ & Term of appointment**	:	w.e.f. 18th September, 2026 for the consecutive period of 3 Years
3	**Brief Profile**	:	Mr. Rihit Mehta is the Whole-time Director of the Company. He holds Bachelor of Engineering, Chemical from University of Mumbai and Master's Degree of Science from the Rutgers, the State University of New Jersey. He overlooks the Production (Technical) and Quality Control department of the Company. He has around 10+ years of experience in the pharmaceutical Industry.
4	**Disclosure of relationships between directors**	:	Immediate relative to Mrs. Rita Mehta, Mr. Harshit Mehta and Mr. Haresh Mehta
5	**Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018**		Mr. Rishit Mehta is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such authority.

Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Wholetime Director of the Company

Sr. No.	Requirement of Disclosure		Details
1	**Reason of change viz. appointment~~, resignation, removal, death or otherwise~~**	:	Mr. Haresh Mehta has re-appointed as Whole-Time Director of the Company w.e.f. 18th September, 2026.
2	**Date of Appointment/~~cessation~~ & Term of appointment**	:	w.e.f. 18th September, 2026 for the consecutive period of 3 Years
3	**Brief Profile**	:	Mr. Haresh Mehta, a founding member, serves as the Chairman Whole time Director & Chief Financial Officer of the Company. He holds Bachelor's Degree of

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • **Website :** www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

			Pharmacy from the University of Bombay and a diploma in Industrial Management from Xavier Institute of Management. He oversees the operations with regards to Financial and Legal departments of the Company. He has approximately 45+ years of experience in pharmaceutical industry.
4	**Disclosure of relationships between directors**	:	Immediate relative to Mrs. Rita Mehta, Mr. Harshit Mehta and Mr. Rishit Mehta
5	**Confirmation in compliance with SEBI Letter dated June 14, 2018 read along with BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018**		Mr. Haresh Mehta is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such authority.

Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Medico Remedies Limited pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015, as amended

To

THE BOARD OF DIRECTORS

MEDICO REMEDIES LIMITED

1105/1106, 11th Floor, Hubtown Solaris

Opp. Telli Galli, N S Phadke Marg,

Andheri East, Mumbai - 400069

Dear Sirs,

Re: Limited Review Report of the Unaudited Standalone Financial Results for the quarter ended 30th June, 2026

We have reviewed the accompanying Statement of unaudited Standalone Financial Results of Medico Remedies Limited ("the Company") for the quarter ended 30th June 2026 together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing Regulations").

This Statement which is the responsibility of the Company's Management has been reviewed by Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Shah Shroff & Associates
MUMBAI
FRN 128920W
Chartered Accountants

A703, Winsway Complex, Old Police Lane, Andheri (E), Mumbai - 400 069.
Tel.: +91-22 - 6127 7488 / 6697 3268 Email : shahshroff@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standard specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We have reviewed the financial results for quarter ended 30th June 2026. The review for the period from 1st April 2025 to 30th June 2025 was done by the previous auditor (M/s V J Shah & Co) of the Company. We have not performed any procedures for those periods, and our report is not modified in respect of those matters.

For Shah Shroff & Associates

Chartered Accountants

Firm Registration No.: 128920W

Shah Shroff & Associates
MUMBAI
FRN 128920W
Chartered Accountants

Yashesh Shroff

Partner

Membership Number – 103277

UDIN: 26103277KOQRFR3177

Place: Mumbai

Date: 13.08.2026

MEDICO REMEDIES LIMITED
CIN: L24230MH1994PLC077187
Statement of Unaudited Standalone Financial Results for the quarter ended on June 30, 2026

(Rs. In lakhs)

Sn	Particulars	Quarter ended			For the Year Ended
		30-Jun-26 (Unaudited)	31-Mar-26 (Audited)	30-Jun-25 (Unaudited)	31-Mar-26 (Audited)
1	**INCOME**				
	(a) Revenue from Operations	6,940.06	5,680.77	3,825.15	20,637.73
	(b) Other Income	116.86	287.39	65.81	593.35
	Total Income (a+b)	**7,056.92**	**5,968.16**	**3,890.96**	**21,231.08**
2	**Expenses**				
	(a) Cost of raw materials consumed	4,719.53	4,034.43	2,870.91	14,858.71
	(b) Purchase of traded goods	120.42	45.59	62.46	441.32
	(c) Changes in inventories of finished goods. work-in progress and traded goods	735.86	-136.39	-199.51	-167.27
	(d) Employee Benefits Expense	195.76	175.54	170.36	739.82
	(e) Finance Costs	40.62	90.38	28.11	180.63
	(f) Depreciation and Amortisation Expense	72.34	80.19	76.90	309.46
	(g) Other Expenses	838.44	846.49	638.33	3,062.45
	Total expenses	**6,722.97**	**5,136.23**	**3,647.55**	**19,425.12**
3	**Profit/(Loss) before Tax (1-2)**	**333.95**	**831.92**	**243.42**	**1,805.96**
4	**Income Tax expenses**				
	a) Current Tax	71.00	288.55	53.58	505.55
	b) Deferred Tax [(charge/(credit)]	11.16	-42.29	8.01	-11.11
	Total Tax Expenses	**82.16**	**246.26**	**61.58**	**494.44**
5	**Profit/(Loss) for the period (3-4)**	**251.80**	**585.66**	**181.83**	**1,311.52**
6	Other comprehensive income not to be reclassified to Profit and Loss in subsequent periods				
	Profit and Loss in subsequent periods				
	Re-measurement gain/(losses) on defined benefit Plans	-3.70	-15.13	0.16	-14.65
	Tax effect [(charge)/credit]	0.93	3.81	-0.04	3.69
	Other comprehensive income/(loss) (net of tax)	**-2.77**	**-11.32**	**0.12**	**-10.96**
7	Total comprehensive income/(loss) for the period (5+6)	**249.03**	**574.34**	**181.95**	**1,300.56**
8	Paid-up equity share capital(Face value per share: Re.2/-)	1,659.68	1,659.68	1,659.68	1,659.68
9	Other Equity excluding revaluation reserve as per the audited balance sheet				5,887.77
10	Earning per Equity Share of face value of Re.2/- each (Not Annualised)				
	Basic EPS (in Rs.)	**0.30**	**0.71**	**0.22**	**1.58**
	Diluted EPS (in Rs.)	**0.30**	**0.71**	**0.22**	**1.58**

For Medico Remedies Limited

Hmehta

Haresh Mehta
Chairman and Whole Time Director
DIN: 01080289

For Medico Remedies Limited

Hhmehta

Harshit Mehta
Managing Director
DIN: 05144280

MEDICO REMEDIES LTD. MUMBAI

Notes:

1. The above unaudited standalone financial results of the company were reviewed and recommended by the audit committee on August 13, 2026 and subsequently approved by the Board of Directors at its meeting held on August 13, 2026. The review report has been filed with stock exchange and is available on the Company's website.

2. The figures for the quarter ended on 31st March 2026 are balancing figures between the audited figures for the year ended 31st March 2026 and reviewed year to date figures upto the third quarter of that financial year.

3. The standalone financial results for the quarter ended on 30th June, 2026 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.

4. The above financial results have been prepared as per IND AS and all standards and requirements of IND AS are complied with by the company.

5. Medico Remedies Limited is a pharmaceutical formulation manufacturing company and the management reviews the performance of the company as a single operating segment in accordance with IND-AS 108 "Operating Segments" notified pursuant to Companies (Accounting Standard) Rules, 2015. Accordingly, no segment information/segment reporting has been furnished within. Details of geographical segments are disclosed below:

PARTICULARS		QE 30.06.2026	QE 31.03.2026
		Amount (Rs. In Lakh)	Amount (Rs. In Lakh)
1)	Sales of products within India	2633.62	274.48
2)	Sales of products Outside India	4269.74	5364.29
	Sub- Total	6903.36	5638.77

6. Previous periods figures have been regrouped / reclassified where required to make them compatible with the figures of current periods.

7. The company does not have any subsidiary/associate/joint venture company as on 30th June 2026.

8. The result for the quarter ended June 30, 2026 is available on the BSE Limited website (URL: www.bseindia.com), NSE Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.medicoremedies.com)

For and on behalf of the board,
For Medico Remedies Limited

Hmehta

Haresh Mehta
Chairman and Whole Time Director
DIN:01080289

Place: Mumbai
Date: August 13, 2026

MEDICO REMEDIES LTD. MUMBAI

Hhmehta

Harshit Mehta
Managing Director
DIN:05144280

Place: Mumbai
Date: August 13, 2026